Safety, Tolerability, and Preliminary Efficacy of NouvNeu001 for the Treatment of Advanced Parkinson’s Disease: A Multi-center, Open Label, Phase 1 Study
Objective: This Phase 1 study aims to evaluate the safety, tolerability, preliminary efficacy, and optimal dose of NouvNeu001 for treating mid to late-stage Parkinson’s disease…Investigation of the mode of action of a new device for the application of therapeutic vibro-tactile stimulation to the fingertips on brain activity
Objective: The development of a new therapeutic glove for the vibro-tactile stimulation of the fingertips was accompanied by investigations on its mode of action on…Differentiated approach to treatment and diagnosis of Parkinson’s disease.
Objective: The anatomical and physiological characteristics of tremor in patients with Parkinson’s disease and essential tremor at the same age significantly influence diagnostic approaches, differentiation…Modeling Levodopa Resistance in Parkinson’s Disease: A Novel Approach Targeting Locus Coeruleus Degeneration
Objective: To develop a Parkinson’s disease (PD) model replicating levodopa (LD) resistance by incorporating degeneration of both the substantia nigra (SN) and locus coeruleus (LC),…Antidepressants Associated with Worsening Dyskinesia in Parkinson’s Disease
Objective: This case report aims to highlight the impact of increasing venlafaxine dose on the worsening of dyskinesias and the onset of ocular dyskinesia³ and…Design of ORCHESTRA Study: Practical Experiences With Foslevodopa/Foscarbidopa Treatment in Advanced Parkinson’s Disease
Objective: To describe the practical management of foslevodopa/foscarbidopa (LDp/CDp) for treating advanced Parkinson’s disease (aPD) in routine clinical practice using data collected through a patient…Transcutaneous Vagus Nerve Stimulation for Gait and Motor Function in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Objective: To evaluate the effects of transcutaneous vagus nerve stimulation (tVNS) on gait, motor function, and freezing of gait (FOG) in patients with Parkinson’s disease…Mucuna pruriens for FOG in Parkinson’s disease, Do we have a solution for this trivial problem?
Objective: To study the effects of Mucuna Pruriens when administered via inhalation route, to alleviated symptoms of Parkinson's disease most importantly freezing of gait. Background: Mucuna…Pharmacological PGC-1α Activation Mitigates Dopaminergic Degeneration in Parkinson’s Disease Via Regulating Mitochondrial Homeostasis
Objective: To understand the role of mitochondrial function in improving the outcomes of Parkinson’s disease (PD) via pharmacologically activating PGC-1α by its synthetic activator ZLN005.…L1CAM and TMEM119 enriched Exosomal markers in Parkinson’s Disease and Progressive Supranuclear Palsy: A Prospective Study
Objective: This study explored longitudinal changes in cellular inflammatory, autophagic mediators in L1CAM and TMEM119-enriched exosomal samples of patients with Parkinson’s disease (PD) and Progressive…
- « Previous Page
- 1
- …
- 50
- 51
- 52
- 53
- 54
- …
- 181
- Next Page »